Found: 25
Select item for more details and to access through your institution.
Breast Conservation After Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: Surgical Results From the BrighTNess Randomized Clinical Trial.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Epirubicin With Cyclophosphamide Followed by Docetaxel With Trastuzumab and Bevacizumab as Neoadjuvant Therapy for HER2-Positive Locally Advanced Breast Cancer or as Adjuvant Therapy for HER2-Positive Pathologic Stage III Breast Cancer: A Phase II Trial of the NSABP Foundation Research Group, FB-5.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Anthracyclines in the Treatment of HER2-Negative Breast Cancer.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2008, v. 100, n. 1, p. 2, doi. 10.1093/jnci/djm277
- By:
- Publication type:
- Article
Long-term outcomes of dual vs single HER2-directed neoadjuvant therapy in NSABP B-41.
- Published in:
- Breast Cancer Research & Treatment, 2023, v. 199, n. 2, p. 243, doi. 10.1007/s10549-023-06881-8
- By:
- Publication type:
- Article
Correction to: Definitive results of a phase III adjuvant trial comparing six cycles of FEC-100 to four cycles of AC in women with operable node-negative breast cancer: the NSABP B-36 trial (NRG Oncology).
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice
Definitive results of a phase III adjuvant trial comparing six cycles of FEC-100 to four cycles of AC in women with operable node-negative breast cancer: the NSABP B-36 trial (NRG Oncology).
- Published in:
- Breast Cancer Research & Treatment, 2022, v. 193, n. 3, p. 555, doi. 10.1007/s10549-021-06417-y
- By:
- Publication type:
- Article
Behavioral and health outcomes from the NRG Oncology/NSABP B-36 trial comparing two different adjuvant therapy regimens for early-stage node-negative breast cancer.
- Published in:
- Breast Cancer Research & Treatment, 2022, v. 192, n. 1, p. 153, doi. 10.1007/s10549-021-06475-2
- By:
- Publication type:
- Article
Pathologic complete response and outcomes by intrinsic subtypes in NSABP B-41, a randomized neoadjuvant trial of chemotherapy with trastuzumab, lapatinib, or the combination.
- Published in:
- Breast Cancer Research & Treatment, 2019, v. 178, n. 2, p. 389, doi. 10.1007/s10549-019-05398-3
- By:
- Publication type:
- Article
Ten-year update: NRG Oncology/National Surgical Adjuvant Breast and Bowel Project B-42 randomized trial: extended letrozole therapy in early-stage breast cancer.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2023, v. 115, n. 11, p. 1302, doi. 10.1093/jnci/djad078
- By:
- Publication type:
- Article
Race, Ethnicity, and Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative, Node-Negative Breast Cancer in the Randomized TAILORx Trial.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Stromal Tumor-infiltrating Lymphocytes in NRG Oncology/NSABP B-31 Adjuvant Trial for Early-Stage HER2-Positive Breast Cancer.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Early and Locally Advanced Metaplastic Breast Cancer: Presentation and Survival by Receptor Status in Surveillance, Epidemiology, and End Results (SEER) 2010–2014.
- Published in:
- Oncologist, 2018, v. 23, n. 4, p. 481, doi. 10.1634/theoncologist.2017-0398
- By:
- Publication type:
- Article
Replication of genetic associations of chemotherapy-related cardiotoxicity in the adjuvant NSABP B-31 clinical trial.
- Published in:
- Frontiers in Oncology, 2023, p. 01, doi. 10.3389/fonc.2023.1139347
- By:
- Publication type:
- Article
NRG Oncology/NSABP B-47 menstrual history study: impact of adjuvant chemotherapy with and without trastuzumab.
- Published in:
- NPJ Breast Cancer, 2021, v. 7, n. 1, p. 1, doi. 10.1038/s41523-021-00264-2
- By:
- Publication type:
- Article
21-Gene assay as predictor of chemotherapy benefit in HER2-negative breast cancer.
- Published in:
- NPJ Breast Cancer, 2018, v. 4, n. 1, p. N.PAG, doi. 10.1038/s41523-018-0090-6
- By:
- Publication type:
- Article
T-DM1 Reduces Residual Invasive Disease in Patients with HER2-Positive Breast Cancer After Chemotherapy.
- Published in:
- Journal of Oncology Navigation & Survivorship, 2019, v. 10, n. 5, p. 186
- By:
- Publication type:
- Article
Validation of the NSABP/NRG Oncology 8-Gene Trastuzumab-benefit Signature in Alliance/NCCTG N9831.
- Published in:
- JNCI Cancer Spectrum, 2020, v. 4, n. 5, p. 1, doi. 10.1093/jncics/pkaa058
- By:
- Publication type:
- Article
Role of trastuzumab in the adjuvant treatment of HER2-positive early breast cancer.
- Published in:
- Women's Health (17455057), 2009, v. 5, n. 2, p. 135, doi. 10.2217/17455057.5.2.135
- By:
- Publication type:
- Article
Multifaceted highly targeted sequential multidrug treatment of early ambulatory high-risk SARS-CoV-2 infection (COVID-19).
- Published in:
- 2020
- By:
- Publication type:
- journal article
Phase I and pharmacokinetic study of cisplatin and troxacitabine administered intravenously every 28 days in patients with advanced solid malignancies.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2009, v. 65, n. 1, p. 167, doi. 10.1007/s00280-009-1020-y
- By:
- Publication type:
- Article
Rare subtypes of triple negative breast cancer: Current understanding and future directions.
- Published in:
- NPJ Breast Cancer, 2023, v. 9, n. 1, p. 1, doi. 10.1038/s41523-023-00554-x
- By:
- Publication type:
- Article
Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE.
- Published in:
- NPJ Breast Cancer, 2022, v. 8, n. 1, p. 1, doi. 10.1038/s41523-022-00477-z
- By:
- Publication type:
- Article
Concurrent Bevacizumab with a Sequential Regimen of Doxorubicin and Cyclophosphamide Followed by Docetaxel and Capecitabine as Neoadjuvant Therapy for HER2¯ Locally Advanced Breast Cancer: A Phase II Trial of the NSABP Foundation Research Group.
- Published in:
- Clinical Breast Cancer, 2011, v. 11, n. 4, p. 228, doi. 10.1016/j.clbc.2011.04.001
- By:
- Publication type:
- Article
A Phase II Neoadjuvant Trial of Sequential Nanoparticle Albumin-Bound Paclitaxel Followed by 5-Fluorouracil/Epirubicin/Cyclophosphamide in Locally Advanced Breast Cancer.
- Published in:
- Clinical Breast Cancer, 2010, v. 10, n. 1, p. 81, doi. 10.3816/CBC.2010.n.011
- By:
- Publication type:
- Article
A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma.
- Published in:
- 1999
- By:
- Publication type:
- journal article